[ET Net News Agency, 18 May 2021] Credit Suisse lowered its target price for Everest
Medicines (01952) to HK$108 from HK$110 and maintained its "outperform" rating.
The research house said it expects Gilead's Ph3 data of Trodelvy in HR+/HER2- BC,
Trodelvy potential China approval in 2H21, and continued BD in-licensing deals could
provide positive catalysts for the stock. (RC)